Real World Outcomes in Latin-American Patients with Multiple Myeloma Under 40 Years Old

Nov 18, 2019 | Artículos publicados por GELAMM, Publicaciones


Authors:
 

Humberto Martínez-Cordero, MD, Camila Peña, MD, Natalia Paola Schutz, MDMSc, Virginia Bove, MD, Fiorella Villano, MD, Rocío Osorio, MD, Mauricio Chandia, MD, Cecilia Beltran, MD, Javier Schulz, MD, Daniela Cardemil, MD, Carolina Contreras, MD, Carmen Gloria Vergara, MD, Javiera Donoso, MD, Marcela Espinoza, MD, Gabriel La Rocca, MD, Hernán López-Vidal, MD, Pilar León, MD, Macarena Alejandra Roa Salinas, Christine Rojas, MD, Pablo Soto, MD, Sandra Aranda, MD, Vivianne Torres, MD, Paola Ochoa, MD, Patricio Duarte, MD, Guillermina Remaggi, MD, Sebastian Yantorno, MD, Ariel Corzo, MD, Soledad Zabaljauregui, MD, Claudia Shanley, MD, Sergio Lopresti, MD, Sergio Orlando, MD, Veronica Verri, MD, Luis Darío Quiroga, MD, Juan Jose Garcia, MD, Vanesa Fernandez, MD, Dorotea Fantl, MD, Jhoanna Ramirez, MD, Alicia Molina, MD, Pilar Papilco, MD, Alex Mite, MD, Ines Reyes, MD, Brenner Sabando, Francisca M. Ramirez Aspiazu, MD, Claudia Lucia Sossa, MD, Virginia Abello, MD, Henry Idrobo, MD Professor, Domingo Saavedra, MD, Guillermo Quintero, MD MBA, Lina Gaviria, MD, Rigoberto Gomez, MD, Monica Osuna Pérez, MD, Alicia Henao-Uribe, MD, Luz del Carmen Tarín Arzaga, MD, Omar Cantú-Martínez, MD, David Gomez-Almaguer, MD, Yarely Itzayana García-Navarrete, MD, Antonio Cruz-Mora, MD, Yahveth Cantero-Fortiz, MD, Guillermo J. Ruiz-Arguelles, FRCP, MACP, Eloisa Riva, MD

Abstract:

Multiple myeloma (MM) is a heterogeneous disease that is most frequently diagnosed in the elderly. Therefore, data on clinical characteristics and outcomes in the young population are scarce and it is recognized that it remains incurable even in this group of patients. We present here the outcomes of patients under 40 years old cohort in Latin-American countries. On behalf of GELAMM (Grupo de Estudio Latino-Americano de Mieloma Múltiple).

Publication:

Blood (2019) 134 (Supplement_1): 5508. https://doi.org/10.1182/blood-2019-130987